H.C. Wainwright Reiterates Buy Rating on OKYO Pharma Ltd. (OKYO)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $7.00 price target on OKYO Pharma Ltd. (NASDAQ: OKYO).

The analyst commented: "Yesterday, OKYO Pharma announced that it had a successful Type C meeting with the FDA regarding the Phase 2b/3 trial of urcosimod for the treatment of neuropathic corneal pain (NCP). Key highlights from the meeting include (1) FDA confirmed the approach that the proposed primary endpoint of the Visual Analogue Scale (VAS) pain reduction at Week 12 is clinically meaningful, including explicit acknowledgment that a ≥2-point improvement on the VAS scale represents a meaningful treatment effect; (2) FDA provided statistical guidance to enhance robustness; (3) FDA endorsed the proposed study design, sample size (n=120), and powering assumptions, and agreed that the Ocular Pain Assessment Survey (OPAS) is appropriate as supportive quality-of-life evidence; and (4) FDA alignment on the Chemistry, Manufacturing and Controls (CMC) strategy and key clinical elements, with no material issues raised. With the FDA’s endorsement, the company is slated to initiate the Phase 2b/3 trial in 1H26. We reiterate our Buy rating and $7 PT."

For an analyst ratings summary and ratings history on OKYO Pharma Ltd. click here. For more ratings news on OKYO Pharma Ltd. click here.

Shares of OKYO Pharma Ltd. closed at $2.19 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating